|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,114.55 INR | +0.67% |
|
+12.65% | +23.52% |
Business description: Strides Pharma Science Limited
Number of employees: 3,301
Sales by Activity: Strides Pharma Science Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Pharmaceutical Business (Excl. Bio-Pharmaceutical Business) | 33.16B | 30.7B | 36.88B | 40.51B | 45.65B |
Geographical breakdown of sales: Strides Pharma Science Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
North America | 16.65B | 12.06B | 19.26B | 21.48B | 24.51B |
Europe | 7.32B | 6.77B | 8.37B | 9.2B | 9.94B |
Africa | 5.21B | 5.71B | 4.51B | 3.91B | 4.62B |
Australia | 2.45B | 3.17B | 3.12B | 3.71B | 4.4B |
Unallocated | - | 482M | 807M | 1.6B | 1.74B |
Asia (Excluding India) | 623M | 1.97B | 461M | 172M | 225M |
India | 806M | 473M | 219M | 331M | 160M |
Others | 93.14M | 66.78M | 144M | 116M | 76.43M |
Executive Committee: Strides Pharma Science Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Badree Komandur
CEO | Chief Executive Officer | - | 2024-05-31 |
Vikesh Kumar
DFI | Director of Finance/CFO | 42 | 2024-05-31 |
| Chief Tech/Sci/R&D Officer | - | 2024-11-20 | |
R. Anil Kumar
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | 2017-02-02 |
Composition of the Board of Directors: Strides Pharma Science Limited
| Director | Title | Age | Since |
|---|---|---|---|
Arun N. Kumar
CHM | Chairman | 65 | - |
| Director/Board Member | 82 | 2017-05-17 | |
| Director/Board Member | 58 | 2019-12-10 | |
| Director/Board Member | 64 | 2024-01-31 | |
| Director/Board Member | - | 2026-05-31 | |
| Director/Board Member | 67 | 2024-05-31 | |
| Director/Board Member | - | - | |
Mukta Arora
BRD | Director/Board Member | - | 2025-01-31 |
Holdings: Strides Pharma Science Limited
| Name | Stocks | % | Valuation |
|---|---|---|---|
| 1,839,900 | 1.6% | 35 M $ |
Company details: Strides Pharma Science Limited
Group companies: Strides Pharma Science Limited
| Name | Category and Sector |
|---|---|
Arco Lab Pvt Ltd.
 Arco Lab Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Provides life sciences consulting, digital technology and business services |
Miscellaneous Commercial Services
|
Arco Lab Pvt Ltd.
Arco Lab Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Provides life sciences consulting, digital technology and business services |
Miscellaneous Commercial Services
|
Strides Pharma Global Pte Ltd.
 Strides Pharma Global Pte Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company whose subsidiaries manufactures & distributes pharmaceutical products |
Pharmaceuticals: Major
|
Strides Pharma UK Ltd.
 Strides Pharma UK Ltd. Medical DistributorsDistribution Services Wholesales over-the-counter pharmaceutical products |
Medical Distributors
|
Strides Pharma UK Ltd.
Strides Pharma UK Ltd. Medical DistributorsDistribution Services Wholesales over-the-counter pharmaceutical products |
Medical Distributors
|
Generic Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.03% | +1.40% | +10.40% | +81.61% | 46.28B | |
| +2.46% | +5.97% | +51.91% | +96.77% | 34.73B | |
| -0.04% | -2.41% | -9.89% | +33.50% | 11.56B | |
| +0.67% | -3.39% | +11.49% | +92.80% | 11.32B | |
| +0.95% | +3.33% | +39.31% | +130.57% | 9.27B | |
| +1.19% | +2.49% | +14.70% | +42.99% | 7.13B | |
| +1.22% | +1.77% | +44.21% | -17.25% | 6.6B | |
| +0.12% | -0.21% | +28.88% | +234.15% | 6.39B | |
| -0.63% | -3.58% | -37.81% | -7.82% | 4.98B | |
| Average | +0.65% | +0.02% | +17.02% | +76.37% | 15.36B | |
| Weighted average by Cap. | +0.82% | +1.07% | +22.11% | +82.72% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- STAR Stock
- STAR Stock
- Company Strides Pharma Science Limited
Select your edition
All financial news and data tailored to specific country editions
